| Cat.No. | Name | Information |
|---|---|---|
| M43929 | Zigakibart | Zigakibart is an anti-APRIL monoclonal antibody that can be used in studies related to IgA nephropathy (IgAN). |
| M40986 | NGM-313 | NGM-313 is a β-Klotho/FGFR1c-targeted monoclonal antibody for studies related to non-alcoholic steatohepatitis (NASH). |
| M40938 | Rat IgG2a Isotype Control In vivo | Rat IgG2a Isotype Control In vivo can be used as an isotype-matched control for rat IgG2a antibodies. |
| M40937 | Suciraslimab | Suciraslimab is a potentially first-in-class monoclonal antibody against the B-cell target CD22, which can help change CD22 from cis-binding to trans-binding and form a stable CD22 trans-binding structure, thereby restoring B-cell tolerance to its own antigens and inhibiting B-cells from undergoing a series of related immune responses to attack its own organism. |
| M40905 | Remternetug | Remternetug is an IgG1 monoclonal antibody that targets the pyroglutamate modification of the third amino acid of the amyloid beta peptide present only in brain amyloid plaques, and can be used in studies related to Alzheimer's disease (AD). |
| M40870 | RVT-3101 | RVT-3101 is a potential first-in-class anti-tumor necrosis factor (TNF)-like ligand 1A (TL1A) monoclonal antibody for use in studies related to inflammatory bowel disease (IBD). |
| M40646 | CDX-1140 | CDX-1140 is an anti-CD40 human IgG2 monoclonal antibody that activates dendritic cells and B cells and drives NF-kB stimulation in CD40-expressing reporter cell lines. |
| M40611 | PF-04236921 | PF-04236921 is a fully human IgG2 monoclonal antibody targeting the interleukin IL-6 for studies related to Crohn's disease and rheumatoid arthritis. |
| M40597 | Ametumumab | Ametumumab is a recombinant fully human anti-EGFR monoclonal antibody that can be used in studies related to colorectal cancer. |
| M40596 | Pimurutamab | Pimurutamab is a monoclonal antibody to EGFR that can be used in tumor-related studies. |
| M40594 | Genolimzumab | Genolimzumab is a PD-1 monoclonal antibody that can be used in studies related to peripheral T-cell lymphoma (PTCL). |
| M40593 | Brolucizumab | Brolucizumab is a humanized single-chain anti-VEGF-A variable antibody fragment (scFv) that can be used in studies related to macular degeneration. |
| M40552 | Osemitamab | Osemitamab (TST001) is a recombinant humanized, IgG1 antibody targeting CLDN18.2, consisting of the human mouse monoclonal TST001 γ-1 chain polymerized via disulfide bonding with the human mouse monoclonal TST001 κ-chain dimer (ACI). It can be used in studies related to bile duct tumors. |
| M31299 | Zebituzumab | Zebituzumab (zebituzumab) is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody that can be used in studies related to CD20-positive diffuse large B-cell lymphoma. |
| M25367 | Amlitelimab | Amlitelimab is a potential best-in-class (mAb) anti-OX40 ligand (OX40L) monoclonal antibody.Amlitelimab inhibits OX40-OX40L interaction and may be used in studies related to atopic dermatitis. |
| M25262 | Ordesekimab | Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD). |
| M25184 | Romlusevimab | Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). |
| M25183 | Amubarvimab | Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants. |
| M25168 | Ormutivimab | Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model. |
| M25159 | Manfidokimab | Manfidokimab (AK120) is an anti-interleukin 4 receptor alpha (IL-4Rα) IgG4 monoclonal antibody. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
